Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK Boosts Its Infectious Disease Portfolio With Brexafemme License

Mar 30 2023

• By Joseph Haas

GSK HQ — GSK adds a novel antifungal to its infectious disease portfolio • Source: Shutterstock

Related Content

Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic

Sep 22 2022

Scynexis Data Show Brexafemme Prevents VVC Recurrence

Feb 10 2022

Asia Deal Watch: Genexine Teams With KGBio In Immuno-Oncology, COVID-19 Therapy

Feb 18 2021

Scynexis Prepares To Launch Brexafemme In Vaginal Yeast Infections, Priced At $475

Jul 01 2021

Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis

Dec 06 2021

Scynexis Switches Focus To Hospital Indications For Ibrexafungerp

Oct 21 2022

GSK Hails Success For Novel Antibiotic – But Reaching $1bn Sales Will Be A Challenge

Nov 03 2022

Related Companies

GSK plc

Scynexis, Inc.

Hansoh Pharmaceutical Group Company Limited

Spero Therapeutics, Inc.

Additional Topics

Deals Business Strategies Commercial Infectious Diseases BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.